{"database": "openregs", "table": "documents", "rows": [["FDA-2020-D-1136-0050", "FDA", "FDA-2020-D-1136", "Development of Monoclonal Antibody Products Targeting SARS-CoV-2, Including Addressing the Impact of Emerging Variants, During the COVID-19 Public Health Emergency - Guidance for Industry - February 2021", "Other", "Guidance", "2021-02-22T05:00:00Z", 2021, 2, "2021-02-22T05:00:00Z", null, "2024-11-12T23:30:16Z", null, 1, 0, "0900006484a459a4"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2020-D-1136-0050"], "units": {}, "query_ms": 113.6429839534685, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}